China's Ascletis raises $20M for hep C R&D

Chinese biotech Ascletis raised $20 million from Goldman Sachs ($GS) to advance its pipeline of treatments for hepatitis C and invest in R&D infrastructure. The latest equity investment comes just a few months after the company closed a $35 million round, and Ascletis plans to spend its new cash on an ongoing Phase II study of a hep C combination therapy, now underway in Taiwan. The Hangzhou-headquartered company is also earmarking funds for the construction of a manufacturing facility. Release

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.